Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).
Dörner T, Schulze-Koops H, Burmester GR, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters MA, Tony HP. Dörner T, et al. Among authors: kellner h. Clin Exp Rheumatol. 2019 Nov-Dec;37(6):937-945. Epub 2019 Apr 16. Clin Exp Rheumatol. 2019. PMID: 31025930 Free article. Clinical Trial.
Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care.
Behrens F, Burmester GR, Feuchtenberger M, Kellner H, Kuehne C, Liebhaber A, Wassenberg S, Gerlach J, Zortel M, Hofmann MW, Amberger C. Behrens F, et al. Among authors: kellner h. Clin Exp Rheumatol. 2022 Mar;40(3):551-559. doi: 10.55563/clinexprheumatol/yu55rd. Epub 2021 May 14. Clin Exp Rheumatol. 2022. PMID: 34001304 Free article.
ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis.
Specker C, Alberding A, Aringer M, Burmester GR, Flacke JP, Hofmann MW, Kästner P, Kellner H, Moosig F, Sieburg M, Tony HP, Fliedner G. Specker C, et al. Among authors: kellner h. Clin Exp Rheumatol. 2021 Mar-Apr;39(2):319-328. doi: 10.55563/clinexprheumatol/3qdgi1. Epub 2020 Jul 10. Clin Exp Rheumatol. 2021. PMID: 32662413 Free article.
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).
Behrens F, Koehm M, Rossmanith T, Alten R, Aringer M, Backhaus M, Burmester GR, Feist E, Herrmann E, Kellner H, Krueger K, Lehn A, Müller-Ladner U, Rubbert-Roth A, Tony HP, Wassenberg S, Burkhardt H. Behrens F, et al. Among authors: kellner h. Rheumatology (Oxford). 2021 Nov 3;60(11):5318-5328. doi: 10.1093/rheumatology/keab153. Rheumatology (Oxford). 2021. PMID: 33738492 Free PMC article. Clinical Trial.
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester GR, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U; German Society of Rheumatology. Albrecht K, et al. Among authors: kellner h. Rheumatol Int. 2014 Jan;34(1):1-9. doi: 10.1007/s00296-013-2848-3. Epub 2013 Aug 14. Rheumatol Int. 2014. PMID: 23942828 Review.
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).
Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Burmester GR, et al. Among authors: kellner h. Ann Rheum Dis. 2011 May;70(5):755-9. doi: 10.1136/ard.2010.139725. Epub 2010 Dec 27. Ann Rheum Dis. 2011. PMID: 21187298 Free PMC article. Clinical Trial.
[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].
Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K. Fiehn C, et al. Among authors: kellner h. Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y. Z Rheumatol. 2018. PMID: 29968101 Review. German.
313 results